JP2025514763A - Ｆｃガンマ受容体への結合が低減されたキメラ重鎖定常ドメイン及びその使用 - Google Patents

Ｆｃガンマ受容体への結合が低減されたキメラ重鎖定常ドメイン及びその使用 Download PDF

Info

Publication number
JP2025514763A
JP2025514763A JP2024561852A JP2024561852A JP2025514763A JP 2025514763 A JP2025514763 A JP 2025514763A JP 2024561852 A JP2024561852 A JP 2024561852A JP 2024561852 A JP2024561852 A JP 2024561852A JP 2025514763 A JP2025514763 A JP 2025514763A
Authority
JP
Japan
Prior art keywords
seq
amino acid
domain
constant domain
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024561852A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025514763A5 (https=
Inventor
スハシニ アヴァル、ナガ
デイビス、サミュエル
リン、チャ－ヤン
シェン、ヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2025514763A publication Critical patent/JP2025514763A/ja
Publication of JP2025514763A5 publication Critical patent/JP2025514763A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024561852A 2022-04-21 2023-04-20 Ｆｃガンマ受容体への結合が低減されたキメラ重鎖定常ドメイン及びその使用 Pending JP2025514763A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263333293P 2022-04-21 2022-04-21
US63/333,293 2022-04-21
PCT/US2023/066036 WO2023205753A1 (en) 2022-04-21 2023-04-20 Chimeric heavy chain constant domains with reduced binding to fc gamma receptors and uses thereof

Publications (2)

Publication Number Publication Date
JP2025514763A true JP2025514763A (ja) 2025-05-09
JP2025514763A5 JP2025514763A5 (https=) 2026-04-28

Family

ID=86425985

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024561852A Pending JP2025514763A (ja) 2022-04-21 2023-04-20 Ｆｃガンマ受容体への結合が低減されたキメラ重鎖定常ドメイン及びその使用

Country Status (8)

Country Link
US (1) US20250109207A1 (https=)
EP (1) EP4511398A1 (https=)
JP (1) JP2025514763A (https=)
KR (1) KR20250007564A (https=)
CN (2) CN117597365A (https=)
AU (1) AU2023255761A1 (https=)
CA (1) CA3249454A1 (https=)
WO (1) WO2023205753A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240252601A1 (en) 2022-12-23 2024-08-01 Regeneron Pharmaceuticals, Inc. Ace2 fusion proteins and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
DE69309472T2 (de) 1992-01-23 1997-10-23 Merck Patent Gmbh, 64293 Darmstadt Fusionsproteine von monomeren und dimeren von antikörperfragmenten
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
GB9824437D0 (en) 1998-11-06 1999-01-06 Ylo Herttuala Seppo Gene therapy
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
WO2005049094A1 (en) 2003-11-13 2005-06-02 Advantagene, Inc. A mixed complementary viral vector for gene therapy
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
US8703132B2 (en) * 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
MY192182A (en) * 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
ES2623912T3 (es) * 2010-12-23 2017-07-12 Janssen Biotech, Inc. Mutantes FC de anticuerpo activo resistente a proteasa
CN105026430B (zh) 2012-11-28 2025-03-25 酵活英属哥伦比亚有限公司 工程化免疫球蛋白重链-轻链对及其用途
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
ES2821753T3 (es) 2013-03-15 2021-04-27 Lilly Co Eli Procedimientos de producción de Fab y de anticuerpos biespecíficos
WO2016161010A2 (en) 2015-03-30 2016-10-06 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
MX2022005330A (es) 2019-11-05 2022-05-26 Regeneron Pharma Moleculas de union multiespecificas con scfv en el extremo nterminal.
US12486321B2 (en) * 2020-01-21 2025-12-02 Tavotek Biotechnology (Jiangsu) Co., Ltd Agents that interfere with IL-1BETA receptor signalling

Also Published As

Publication number Publication date
CN119546637A (zh) 2025-02-28
EP4511398A1 (en) 2025-02-26
US20250109207A1 (en) 2025-04-03
WO2023205753A1 (en) 2023-10-26
CA3249454A1 (en) 2023-10-26
KR20250007564A (ko) 2025-01-14
CN117597365A (zh) 2024-02-23
AU2023255761A1 (en) 2024-11-07

Similar Documents

Publication Publication Date Title
TWI830761B (zh) 針對cldn18.2和cd3之抗體構建體
TWI732136B (zh) 新型雙特異性cd3/cd19多肽複合物
KR101431344B1 (ko) 이중 특이성 4가 항원 결합 단백질
CN113301919B (zh) 激活免疫细胞的双特异性抗体
TW202212361A (zh) 結合cd3之抗體
TW201102087A (en) Bispecific antigen binding proteins
CN108290959A (zh) 四价多特异性抗体
CN106164095A (zh) 多特异性抗体
CA3157075A1 (en) N-terminal scfv multispecific binding molecules
TW202216767A (zh) 與ＣＤ３及ＦｏｌＲ１結合之抗體
CN106397598A (zh) 多价多特异性抗体及免疫杂合蛋白的表达和制备方法
US12559576B2 (en) CD20-PD1 binding molecules and methods of use thereof
US20250109207A1 (en) Chimeric heavy chain constant domains with reduced binding to fc gamma receptors and uses thereof
US20260098090A1 (en) Fusions with cd8 antigen binding molecules for treating chronic viral infection
US20250339519A1 (en) Combination of cytokine fusion proteins with cd8 antigen binding molecules
JP2024517844A (ja) 多重特異性ｆｇｆ２１受容体アゴニスト及びそれらの使用
HK40116913A (zh) 与FCγ受体的结合降低的嵌合重链恒定结构域及其用途
US20250011449A1 (en) Circularized antibody molecules
US20260055171A1 (en) Vegf antagonists and methods of use thereof
CN121057744A (zh) 多价抗刺突蛋白结合分子及其用途
CN121873202A (zh) Il-2突变体、pd1抗体×il-2突变体融合蛋白及其应用
HK40102926A (zh) 带电荷对的双特异性抗体及其应用
CN120958019A (zh) 针对人分化簇3蛋白的抗体及其变体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260420

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260420